Bibliography
- REYNOLDS GP: What is an atypical antipsychotic? J. Psychopharmacol. (1997) 11:195–199.
- •A review of the concept of atypicality, its experimental models and correlates, and the proposed pharmacological mechanisms that may contribute to it.
- SEEMAN P, TALLERICO T: Rapid release of antipsychotic drugs from dopamine D 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry (1999) 156:876–884.
- •An interesting hypothesis relating weak effects of antipsychotics at the D2 receptor to aspects of atypicality.
- LUND BC, PERRY PJ: Olanzapine: an atypical antipsychotic for schizophrenia. Exp. Opin. Pharmacother. (2000) 1(2)305–323.
- TECOTT LH, SUN LM, AKANA SF et al: Eating disorder and epilepsy in mice lacking 5-11T2c serotonin receptors. Nature (1995) 374:542–546.
- •Potentially an important observation indicating that 5-HT2c antagonism may underlie the weight gain induced by some antipsychotic drugs.
- SCHOTTE A, JANSSEN PFM, GOMMEREN W et al.: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (1996) 124:57–73.
- •A comprehensive assessment of the affinities of several current and potential antipsychotic drugs for a wide range of neurotransmitter receptors.
- DAVIS R, MARKHAM A: Ziprasidone. CNS Drugs (1997) 8:153–159.
- TOLLEFSON GD, SANGER TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry (1997) 154:466–474.
- KING DJ: Atypical antipsychotics and the negative symptoms of schizophrenia. Adv. Psychial Treatment (1998) 4:53–61.
- •A valuable review of controlled trials of the efficacy of antipsychotic drugs against negative symptoms.
- BRAR JS, CHENGAPPA KN, PAREPALLY H et al.: Theeffects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann. Clin. Psychiatry (1997) 9:227–234.
- LOO H, POIRER-LITTRE M-F, THERON M et al.:Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry (1997) 170:18–22.
- PERRAULT G, DEPOORTERE R, MOREL E, SANGER DJ, SCATTON B: Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol Exp. Ther. (1997) 280:73–82.
- MELTZER HY, OKAYLI G Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry (1995) 152:183–190.
- COUKELL AJ, SPENCER CM, BENFIELD P: Amisulpride. CNS Drugs (1996) 6:237–256.
- •A review of the pharmacology and therapeutic efficacy of amisulpride in the treatment of schizophrenia.
- COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS: Evaluating the effects of antipsychotics on cognition in schizophrenia. J. Clin. Psychiatry (1998) 59\(Suppl. 12):35–40.
- HAAPALINNA A, SIRVIO J, LAMMINTAUSTA R: Facilita-tion of cognitive functions by a specific alpha2-adrenoceptor antagonist, atipamezole. Eur. J. Pharmacol. (1998) 347:29–40.
- MAYER-LINDENBERG A, GRUPPE H, BAUER U, LIS S, KRIEGER S, GALLHOFER B: Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry (1997) 30:35–42.
- NEEDHAM PL, ATKINSON J, SKILL MJ, HEAL DJ: Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol. Bull. (1996) 32:123–128.
- BOWEN DM, FRANCIS PT, PANGALOS MN, STEPHENS PH, PROCTOR AW: Treatment strategies for Alzheimer's disease. Lancet (1992) 339:132.
- •This letter noted the effects of 5-HTIA drugs on cortical glutamatergic neurones and indicated a possible clinical application.
- TRICHARD C, PALLIERE-MARTINOT ML, ATTAR-LEVY D, RECASSENS C, MONNET F, MARTINOT JL: Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine and amisulpride in schizophrenic patients. Am. J. Psychiatry (1998) 155:505–508.